{"filings":[{"id":1691598,"accession_number":"0001104659-26-084242","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-07-16T20:05:45+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Outlook Therapeutics stockholders approve authorized share increase and reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 260M to 600M shares via Certificate of Amendment filed July 16, 2026.","Reverse stock split approved at ratio 1:10 to 1:50, with exact ratio to be set by board of directors.","Stockholders approved issuance of shares underlying warrants from April 2026 private placement (up to 16.1M shares) and placement agent warrants.","Special meeting quorum was 51.5% (62.3M of 120.9M outstanding shares present or represented).","Proposal 2 (authorized share increase) passed with 24.4M for, 8.7M against; Proposal 3 (reverse split) passed with 44.3M for, 17.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1306676,"accession_number":"0001104659-26-078337","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-06-26T21:30:25+00:00","items":["3.01"],"status":"ready","headline":"Outlook Therapeutics regains Nasdaq minimum bid price compliance, delisting risk removed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter on June 26, 2026 confirming compliance with bid price rule 5550(a)(2).","Closing bid price was $1.00 or greater for ten consecutive business days from June 11-25, 2026.","Prior delisting notice from February 18, 2026 for failing minimum bid price is now closed.","Common stock (OTLK) remains listed on Nasdaq Capital Market without further action needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1066596,"accession_number":"0001104659-26-074346","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-06-16T12:46:01+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts resubmitted BLA for Outlook's ONS-5010; PDUFA date July 29, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA acknowledged receipt of resubmitted BLA for ONS-5010 (bevacizumab-vikg) to treat wet AMD.","Class 1 review with 60-day review period; PDUFA target action date set for July 29, 2026.","If approved, ONS-5010 would be first FDA-approved ophthalmic bevacizumab with standardized manufacturing & labeling.","Company has initiated pre-launch activities in anticipation of potential BLA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":760876,"accession_number":"0001104659-26-068659","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-06-01T13:15:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmitted BLA for ONS-5010 (bevacizumab-vikg) for neovascular AMD under Class 1 review.","FDA OND concluded substantial evidence of effectiveness established; no additional trials required.","PDUFA target decision date expected within 60 days of FDA receipt of resubmission.","Resubmission follows successful appeal of December 2026 Complete Response Letter.","If approved, ONS-5010 would be first FDA-approved ophthalmic formulation of bevacizumab."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":747560,"accession_number":"0001104659-26-068306","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-05-29T20:30:49+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics sells 8.54M shares to GMS Ventures in registered direct offering","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["8,539,709 shares of common stock sold to GMS Ventures and Investments under a securities purchase agreement dated May 28, 2026.","Offering made via effective S-3 shelf registration statement (File No. 333-278340).","No per-share price or gross proceeds disclosed in the filing.","Shares issued under a registered direct offering; closing expected on or about May 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":724159,"accession_number":"0001104659-26-067614","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-05-28T21:09:53+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics raises ~$5M in registered direct offering at $0.5855/share; warrants repriced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$5.0M from sale of 8,539,709 shares at $0.5855 per share.","Warrant amendment reduces exercise price of 15,488,570 warrants from $1.78 to $0.5855.","Offering expected to close May 29, 2026; net proceeds for working capital and general corporate purposes.","Purchaser GMS Ventures is affiliated with directors Yezan Haddadin and Faisal G. Sukhtian."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649236,"accession_number":"0001104659-26-065992","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-05-26T11:15:41+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Outlook Therapeutics appeal; BLA resubmission planned for June 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA concluded substantial evidence of effectiveness for LYTENAVA (bevacizumab-vikg) for nAMD after FDR appeal.","Company will resubmit BLA as Class 1 in June 2026; PDUFA decision expected within 60 days.","Appeal resolves December 30, 2025 Complete Response Letter; FDA directs final labeling discussions.","NORSE TWO trial results plus confirmatory data from NORSE EIGHT and other evidence supported effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":481479,"accession_number":"0001104659-26-062865","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-05-15T23:55:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outlook Therapeutics Q2 FY2026 net loss narrows to $4.5M; FDA decision on ONS-5010 expected May 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.5M ($0.05/sh) vs $46.4M ($1.50/sh) YoY; adjusted net loss $14.1M ($0.16/sh).","LYTENAVA unit sales in Europe down ~10% QoQ; cost reduction steps initiated to improve margins.","Cash $7.7M as of Mar 31; raised ~$4M in March offering and $4.2M net in April registered direct offering.","FDA formal dispute resolution meeting completed in April; written decision expected within May 2026.","Entered Swiss distribution agreement with Mediconsult AG; targeting 2027 launch pending marketing authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":69281,"accession_number":"0001104659-26-060305","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-05-13T20:36:26+00:00","items":["1.01","1.02","2.02","9.01"],"status":"ready","headline":"Outlook Therapeutics enters new $100M ATM with H.C. Wainwright; cash at $7.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into $100M at-the-market offering agreement with H.C. Wainwright & Co. as sales agent.","Prior $100M ATM with BTIG terminated effective May 12, 2026.","Preliminary cash and cash equivalents of $7.7M as of March 31, 2026 (unaudited), plus $4.5M from April 2026 direct offering.","H.C. Wainwright will receive a 3% commission on gross proceeds from shares sold under the ATM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94395,"accession_number":"0001104659-26-047741","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics raises ~$5M in registered direct offering and private placement at $0.31/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 16,129,033 shares of common stock and accompanying Common Warrants at $0.31 per unit.","Gross proceeds approximately $5.0 million; net proceeds for working capital and general corporate purposes.","Common Warrants exercisable at $0.31 per share, subject to stockholder approval and increase in authorized shares.","Concurrent warrant amendment reduces exercise price of 2,142,854 existing warrants from $2.26 to $0.31.","H.C. Wainwright acted as placement agent with 7.0% cash fee and warrants for 1,129,032 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94394,"accession_number":"0001104659-26-046014","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics completes FDA dispute resolution meeting for ONS-5010; decision expected May 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed Federal Dispute Resolution meeting with FDA Office of New Drugs to appeal Dec 30, 2025 Complete Response Letter for ONS-5010 BLA.","Meeting addressed regulatory pathway for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AMD.","Formal FDA decision expected in May 2026; company will update after receipt.","Follows Type A meeting with Division of Ophthalmology; CEO Bob Jahr cites constructive dialogue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94393,"accession_number":"0001104659-26-040387","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics FDA accepts FDRR for ONS-5010; meeting set for April 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab) for wet AMD.","Meeting with deciding official scheduled for April 2026; follows Type A meeting on March 2, 2026.","Company cites NORSE TWO and NORSE EIGHT data supporting efficacy/safety; no safety concerns raised.","If approved, ONS-5010 would be first FDA-approved ophthalmic bevacizumab with standardized manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106754,"accession_number":"0001104659-26-034601","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics closes $5.0M offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["20M shares + 20M warrants sold at $0.25/unit; gross proceeds ~$5.0M, net ~$4.0M.","Warrants exercisable immediately at $0.25, expire in 5 years; includes 4.99%/9.99% beneficial ownership limitation.","H.C. Wainwright placement agent, receiving 7% cash fee and 1.4M warrants at $0.3125.","Company agreed to one-year ban on variable rate transactions and lock-up agreements.","Offering closed March 25, 2026; net proceeds ~$4.0M for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106753,"accession_number":"0001104659-26-028103","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics raises $17M via Atlas note to partially repay Avondale debt; going concern warning","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $18.36M unsecured note (net $17M after OID) to Atlas Sciences; proceeds used to repay $17M of $33.1M Avondale Note.","Remaining Avondale Note balance of ~$10.8M; maturity extended to Dec 31, 2026 via amendment.","Atlas note: interest prime+3% (floor 9.5%), matures 15 months from March 16, 2026; quarterly redemption up to $3M; 7.5% exit fee.","Supplemental risk factors state substantial doubt about going concern; cash insufficient for next 12 months.","FDA issued third Complete Response Letter for ONS-5010 in Dec 2025; Type A meeting held March 2026 with no clear path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106752,"accession_number":"0001104659-26-026465","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Julia Haller resigns from Outlook Therapeutics board, effective March 11, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Julia Haller resigned as Class II director, also serving on Nominating and Corporate Governance Committee.","Board accepted resignation on March 6, 2026, effective March 11, with board size reduced to nine.","Resignation not due to any dispute with company; she cited new CEO duties at Wills Eye Hospital.","Company thanked Dr. Haller for her contributions during her tenure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106751,"accession_number":"0001104659-26-025893","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Outlook Therapeutics annual meeting elects three Class I directors, ratifies KPMG, approves say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Yezan Haddadin, Faisal G. Sukhtian, Kurt J. Hilzinger elected as Class I directors with votes for >12M each.","KPMG LLP ratified as independent auditor for FY2026 with 35.6M votes for, 0.8M against, 0.9M abstain.","Non-binding advisory vote on exec compensation approved: 13.9M for, 1.5M against, 0.4M abstain.","Approximately 50.7% of outstanding shares (37.3M of 73.5M) represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106750,"accession_number":"0001104659-26-024189","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics updates on Type A meeting with FDA for ONS-5010; no definitive resolution","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Type A meeting held with FDA to discuss December 30, 2025 Complete Response Letter for ONS-5010 BLA.","FDA had requested confirmatory evidence of effectiveness; no safety concerns identified by FDA.","Company expects continued discussions to clarify agency views on confirmatory evidence.","ONS-5010 met primary endpoints in Phase 3 NORSE TWO trial; NORSE EIGHT provided confirmatory efficacy/safety data.","If approved, ONS-5010 would be first FDA-approved ophthalmic bevacizumab with US manufacturing supply chain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106749,"accession_number":"0001104659-26-017118","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Outlook Therapeutics receives Nasdaq minimum bid price deficiency notice; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Feb 18, 2026, for closing bid price below $1.00 for 30 consecutive business days.","Has 180 calendar days, until August 17, 2026, to regain compliance.","To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.","If not compliant by Aug 17, may be eligible for additional 180-day period if it meets other standards.","Company will monitor bid price and evaluate options including reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106748,"accession_number":"0001104659-26-015887","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outlook Therapeutics Q1 FY2026 net loss $23.1M; unit sales of LYTENAVA double in Europe","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.1M ($0.38/share) vs net income of $17.4M ($0.72/share) in prior-year quarter.","Adjusted net loss $13.5M ($0.22/share) vs adjusted net loss $21.6M ($0.89/share) a year ago.","Revenue negatively impacted by returns reserve for short-dated product from UK distributor; unit sales more than doubled QoQ.","Cash and equivalents $8.7M as of Dec 31, 2025 (excluding $2.4M ATM proceeds post-quarter).","Submitted Type A meeting request to FDA to discuss ONS-5010 CRL for wet AMD; additional EU launches planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106747,"accession_number":"0001104659-26-013470","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics requests Type A FDA meeting after CRL for wet AMD drug ONS-5010","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CRL dated Dec 30, 2025 cited lack of substantial evidence; company believes it contradicts alignment from Sept 2025 meeting.","Phase 3 NORSE TWO met primary endpoint (15-letter gain at 12 months); NORSE EIGHT missed primary at 8 weeks.","ONS-5010/LYTENAVA is already approved and commercially available in EU and UK for wet AMD.","FDA has not raised safety concerns; company plans to pursue resolution via Type A meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106746,"accession_number":"0001104659-26-000066","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Outlook Therapeutics' ONS-5010 BLA for wet AMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL states additional mechanistic/natural history data does not alter prior conclusion; confirmatory efficacy evidence needed but not defined.","Outlook Therapeutics disagrees with decision and is exploring all available U.S. approval pathways.","ONS-5010 (LYTENAVA) already approved in EU and UK; commercially available in Germany and UK since June 2025.","CEO Bob Jahr reaffirms commitment to bringing first FDA-approved on-label bevacizumab for wet AMD to U.S. patients.","Company continues to expand European presence and seek commercial partners outside Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123063,"accession_number":"0001104659-25-122786","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outlook Therapeutics FY2025 net loss $62.4M; $1.4M revenue from LYTENAVA launch in Europe","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $62.4M ($1.79/share) vs $75.4M ($4.06/share) prior year; revenue $1.4M from initial EU sales.","Cash $8.1M at Sept 30, 2025; $14.9M net from ATM after quarter-end; no debt mentioned.","Expenses fell $4.6M YoY due to lower R&D, partly offset by higher SG&A for European launch.","FDA PDUFA goal date for ONS-5010 is Dec 31, 2025; awaiting U.S. approval decision.","LYTENAVA accepted into UK tender framework in Dec 2025; launch expanding to Austria and Netherlands."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123062,"accession_number":"0001104659-25-111316","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA accepts Outlook Therapeutics' BLA resubmission for ONS-5010; PDUFA date Dec 31, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA acknowledged receipt of BLA resubmission for ONS-5010 (bevacizumab-vikg) and assigned Class 1 review.","Class 1 review results in a two-month review period from resubmission date.","PDUFA goal date set for December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123061,"accession_number":"0001104659-25-105633","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 (wet AMD) to FDA after Sept 2025 Type A meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Resubmitted BLA on Nov 3, 2025 for ONS-5010 (LYTENAVA) to treat wet AMD.","Resubmission follows FDA Type A meeting in Sept 2025; aims to resolve CRL issued Aug 2025.","CEO Bob Jahr says resubmission marks 'important step forward' for potential near-term U.S. approval.","Company accelerating commercial efforts in Europe while positioning for U.S. approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139763,"accession_number":"0001104659-25-094558","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics completes FDA Type A meeting for ONS-5010 BLA; plans resubmission in 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Type A meeting with FDA discussed August 27, 2025 CRL for ONS-5010 BLA (bevacizumab for wet AMD).","Company expects to resubmit BLA before end of calendar year 2025 after reviewing FDA feedback.","CEO Bob Jahr stated productive discussion; written minutes still pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139762,"accession_number":"0001104659-25-087886","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chief Commercial Officer Jeff Evanson departs Outlook Therapeutics effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Evanson stepped down as Chief Commercial Officer on September 5, 2025.","Departure is without 'cause'; eligible for severance benefits per employment agreement.","No replacement named; interim CEO Lawrence Kenyon continues in role.","Company is a biopharmaceutical firm focused on ophthalmic therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139761,"accession_number":"0001104659-25-086428","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter to Outlook Therapeutics for ONS-5010 BLA; lacks efficacy evidence","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CRL cites lack of substantial evidence of effectiveness; ONS-5010 did not meet primary endpoint in NORSE EIGHT trial.","FDA recommends confirmatory evidence; NORSE TWO met primary endpoint but is not sufficient alone.","No other deficiencies in BLA; company plans to meet with FDA to discuss possible path to approval.","ONS-5010/LYTENAVA already approved in EU and UK; commercial launch in Germany and UK began June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139760,"accession_number":"0001104659-25-078622","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outlook Therapeutics reports first LYTENAVA sales, $20.2M net loss for Q3 FY2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First commercial sales of LYTENAVA (bevacizumab gamma) in Germany and UK; $1.5M revenue recognized.","Net loss of $20.2M ($0.55 per share), compared to net loss of $0.89 per share in prior-year quarter.","Adjusted net loss of $15.8M ($0.44 per share), excluding $2.3M change in promissory notes and $2.0M warrant liability.","Cash and cash equivalents of $8.9M as of June 30, 2025.","FDA PDUFA goal date for ONS-5010 (bevacizumab-vikg) set for August 27, 2025."],"consensus_eps_estimate":-0.2584,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":1505322.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139759,"accession_number":"0001104659-25-064755","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Outlook Therapeutics appoints Robert C. Jahr as President and CEO, replacing interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert C. Jahr appointed President & CEO effective July 1, 2025; replaces interim CEO Lawrence Kenyon, who remains CFO and board member.","Base salary $600,000; target annual bonus 70% of base; inducement option for 800,000 shares vesting over 4 years.","Jahr previously Chief Commercial Officer at Sobi NA (2021-2025); held leadership roles at UCB Pharma and Amgen.","Severance: 12 months base salary + target bonus on qualifying termination; 18 months base + 150% bonus on termination in connection with change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157329,"accession_number":"0001104659-25-055521","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Outlook Therapeutics launches LYTENAVA (bevacizumab gamma) in Germany and UK for wet AMD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Commercial launch of LYTENAVA (bevacizumab gamma) in Germany and UK announced on June 2, 2025.","Indication: treatment of wet age-related macular degeneration (wet AMD).","First approved bevacizumab gamma product for wet AMD in these two markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157328,"accession_number":"0001104659-25-052452","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics raises $13M in public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 9,285,714 shares and warrants to purchase 18,571,428 shares at combined price $1.40 per unit.","Gross proceeds of ~$13M; closing expected May 27, 2025.","Warrants exercisable immediately at $1.40/share, expire in 5 years, with beneficial ownership cap.","GMS Ventures (affiliated with directors) committed $6M of the offering.","Underwriting agreement entered with BTIG, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157327,"accession_number":"0001104659-25-049411","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outlook Therapeutics Q2 FY2025 net loss $46.4M; cash $7.6M; PDUFA Aug 27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $46.4M ($1.50/share) vs $114.3M ($8.01) YoY; adjusted net loss $12.5M ($0.40) vs $22.1M ($1.55).","Cash and equivalents $7.6M as of March 31, 2025; no revenue (pre-commercial stage).","LYTENAVA commercial launch in Germany and UK planned for Q2 CY2025.","FDA PDUFA goal date August 27, 2025 for ONS-5010 (bevacizumab-vikg) BLA resubmission.","Warrant inducement expenses $33.9M and other non-cash items drove adjusted loss items."],"consensus_eps_estimate":-0.4012,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157326,"accession_number":"0001558370-25-004726","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Outlook Therapeutics awards $237,500 retention bonus to CFO/Interim CEO Kenyon","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cash retention bonus of $237,500 approved by Compensation Committee on April 9, 2025.","Bonus payable December 31, 2025, contingent on Kenyon's continuous employment through that date.","Kenyon declined option to receive stock options in lieu of cash; no election made.","Upon a qualifying termination before Dec 31, 2025, bonus accelerated subject to release of claims.","Retention bonus letter filed as Exhibit 10.1 with the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157325,"accession_number":"0001558370-25-004606","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA accepts resubmission of OTLK's BLA for ONS-5010; PDUFA date set for August 27, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA acknowledged receipt of resubmission of BLA for ONS-5010 (bevacizumab-vikg).","FDA designated the BLA as a Class 2 review with a six-month review period.","PDUFA goal date for the BLA is August 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175704,"accession_number":"0001558370-25-003013","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["1.02","5.03","5.07","9.01"],"status":"ready","headline":"Outlook Therapeutics closes $33.1M convertible note, increases authorized shares to 260M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued $33.1M convertible note to Avondale Capital on March 13, 2025; proceeds used to repay $32.91M Streeterville note.","Stockholders approved increase in authorized common shares from 60M to 260M, effective March 11.","Annual Meeting elected directors: Julian Gangolli, Ralph Thurman, Lawrence Kenyon to Class III.","Stockholders approved potential issuance of >19.99% of outstanding common stock upon note conversion.","Ratified KPMG as auditor for FY2025; advisory say-on-pay passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175703,"accession_number":"0001104659-25-018717","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 to FDA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmitted Biologics License Application for ONS-5010 to FDA on February 28, 2025.","No details on resubmission content, prior FDA actions, or expected review timeline provided.","Resubmission marks a key regulatory step for the company's sole pipeline candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175702,"accession_number":"0001104659-25-013509","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outlook Q1: GAAP EPS $0.72 (fair value gains), adj EPS -$0.89; BLA resubmission on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $17.4M ($0.72/sh) vs net loss $11.2M; adj net loss $21.6M ($0.89/sh) vs $10.1M ($0.78 loss) prior year.","BLA resubmission for ONS-5010 (bevacizumab-vikg) targeted for Q1 CY2025; potential FDA approval in Q3 CY2025.","First commercial launches of LYTENAVA in Germany and UK planned for Q2 CY2025; collaboration with Cencora announced.","NORSE EIGHT trial missed primary non-inferiority endpoint at week 8; 12-week analysis met non-inferiority margin."],"consensus_eps_estimate":null,"consensus_eps_actual":0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175701,"accession_number":"0001104659-25-008146","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","9.01"],"status":"ready","headline":"Outlook Therapeutics enters $33.1M convertible note with Avondale Capital to refinance Streeterville debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $33.1M unsecured convertible note to Avondale Capital; proceeds primarily used to repay $32.37M Streeterville note.","Note bears interest at prime+3% (floor 9.5%), matures July 1, 2026; conversion price $2.26 per share.","Avondale may convert starting 6 months after issuance or when registration effective; Company can convert if stock ≥$3 for 30 days.","Quarterly debt reduction of at least $3M required; prepayments incur 7.5% exit fee.","Director Lawrence Kenyon reclassified from Class II to Class III to rebalance board classes effective Jan 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175700,"accession_number":"0001104659-25-004159","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics raises ~$20.5M via warrant inductions; ONS-5010 meets noninferiority at week 12 in AMD trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercised existing warrants for ~$17.8M gross (including $8.7M from GMS Ventures) and ~$2.7M from Syntone.","Issued inducement warrants for 14.1M shares (Tranche A immediate, Tranche B subject to shareholder approval) at $2.26 exercise price.","In NORSE EIGHT, ONS-5010 showed +5.5 letters BCVA improvement at week 12, meeting noninferiority (p=0.0043) vs ranibizumab.","Plans to resubmit BLA for ONS-5010 in Q1 2025 based on complete 12-week safety and efficacy data.","No retinal vasculitis reported; safety profile comparable to ranibizumab across all study timepoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192644,"accession_number":"0001104659-24-131957","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outlook Therapeutics reports FY2024 net loss of $75.4M; LYTENAVA launch plans for H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $75.4M ($4.06 per share) vs $59.0M ($4.72 per share) in prior fiscal year.","Cash and cash equivalents of $14.9M as of September 30, 2024.","LYTENAVA (bevacizumab gamma) approved in EU and UK for wet AMD; NICE recommends in UK.","NORSE EIGHT month 3 efficacy data expected January 2025; BLA resubmission targeted Q1 2025.","First commercial launches in UK and Germany planned H1 2025; potential US FDA approval H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192643,"accession_number":"0001104659-24-128901","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Outlook Therapeutics cuts workforce by 23% (5 employees) to preserve capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reduction of 5 employees (~23% of headcount) on Dec 10; effective Dec 13.","Estimated restructuring charges of ~$0.3 million for severance, benefits, and related costs.","Majority of cash payments expected to be substantially complete by end of Q3 2025.","Severance contingent on release of claims; includes COBRA premiums for specified period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192642,"accession_number":"0001104659-24-125350","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Outlook Therapeutics CEO Russell Trenary resigns effective Dec 3; CFO Kenyon named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["C. Russell Trenary III stepped down as President, CEO and Board member on Dec 3, 2024, effective immediately.","Departure is a termination without cause; Trenary will receive severance benefits per his employment agreement.","Board reduced from ten to nine directors upon Trenary's resignation.","CFO Lawrence A. Kenyon, 59, appointed Interim CEO effective Dec 3 while Board searches for permanent CEO.","Kenyon continues as CFO during the interim period; no material arrangements or family relationships disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192641,"accession_number":"0001104659-24-123554","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics' ONS-5010 misses key endpoint in NORSE EIGHT trial; BLA resubmission planned Q1 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ONS-5010 did not meet non-inferiority endpoint at week 8 vs ranibizumab (difference -2.257 BCVA letters, margin -3.5).","Mean BCVA improvement: ONS-5010 +4.2 letters, ranibizumab +6.3 letters (p=0.0863).","Favorable safety profile: no retinal vasculitis, ocular AE rates comparable to ranibizumab.","Final month 3 data expected Jan 2025; BLA resubmission to FDA in calendar Q1 2025.","EU/UK marketing authorization already granted; launch in UK and Germany planned for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209093,"accession_number":"0001104659-24-089325","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outlook Therapeutics reports Q3 FY2024 adjusted net loss $19.2M; EU/UK approval for LYTENAVA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $44.4M ($1.91 basic EPS), but diluted loss $0.89; adjusted net loss $19.2M ($0.83).","Cash and equivalents $32.0M at June 30, 2024; raised $65M from private placements in March/April.","EU and UK granted marketing authorization for LYTENAVA (bevacizumab gamma) for wet AMD.","NORSE EIGHT trial enrollment at 359 of ~400 subjects; topline results expected Q4 CY2024.","BLA resubmission for ONS-5010 on track for Q1 CY2025; US launch anticipated H2 CY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209092,"accession_number":"0001104659-24-078207","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Outlook Therapeutics gets UK MHRA approval for LYTENAVA (bevacizumab gamma) for wet AMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["UK MHRA granted Marketing Authorization for LYTENAVA (bevacizumab gamma) to treat wet age-related macular degeneration.","LYTENAVA is the first and only authorized ophthalmic bevacizumab formulation for wet AMD in the EU and UK.","Approval leveraged EMA positive opinion under the new International Recognition Procedure.","This regulatory milestone supports Outlook's commercial strategy in the UK market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226947,"accession_number":"0001104659-24-065609","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Outlook Therapeutics receives EU marketing authorization for LYTENAVA (bevacizumab gamma) for wet AMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Commission granted Marketing Authorization for LYTENAVA (bevacizumab gamma) for wet AMD in the EU.","LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for wet AMD in the EU.","Approval based on three completed registration trials (NORSE ONE, TWO, THREE) and supporting data.","Marketing authorization applies automatically to all 27 EU member states plus Iceland, Norway, Liechtenstein.","Outlook granted an initial 10 years of market exclusivity in the EU for LYTENAVA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226946,"accession_number":"0001104659-24-062054","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Outlook Therapeutics reports Q2 FY2024 net loss of $114.3M; positive CHMP opinion for ONS-5010 in EU","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $114.3M ($8.01/sh); adjusted net loss of $22.1M ($1.55/sh) vs $6.7M loss year ago.","CHMP issued positive opinion for ONS-5010/LYTENAVA in EU; EC decision expected within ~67 days.","NORSE EIGHT trial >30% enrolled; topline readout planned in Q4 CY2024; BLA resubmission by end of CY2024.","UK MAA submitted under International Recognition Procedure.","Company believes sufficient capital to fund potential FDA approval and commercial launch assuming warrant exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226945,"accession_number":"0001104659-24-060517","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Outlook Therapeutics submits UK MAA for ONS-5010 (bevacizumab gamma) for wet AMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted MAA to UK MHRA via International Recognition Procedure, relying on March 2024 positive CHMP opinion.","ONS-5010 is proposed as the first on-label ophthalmic bevacizumab for wet AMD in the UK.","Clinical program support from three completed registration trials: NORSE ONE, TWO, and THREE.","EU decision on CHMP opinion expected within ~67 days; applies to 27 Member States plus Iceland, Norway, Liechtenstein."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226944,"accession_number":"0001104659-24-055141","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Outlook Therapeutics moves headquarters to Iselin, NJ effective May 1, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["New headquarters address: 111 S. Wood Avenue, Unit #100, Iselin, NJ 08830.","Company telephone number remains unchanged at (609) 619-3990.","Effective date of the headquarters move is May 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226943,"accession_number":"0001104659-24-047322","cik":1649989,"company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Outlook Therapeutics closes $5M private placement to Syntone Ventures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 714,286 shares and warrants to purchase 1,071,429 shares at $7.00 per share+ warrant.","Warrant exercise price is $7.70 per share, expiring April 15, 2029.","Sale relied on Section 4(a)(2) and Rule 506 exemptions without registration.","Syntone Ventures LLC is the sole investor in the private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93910746.74295475,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-04-15T23:59:59+00:00|226943"}